{"id":"W2975057760","doi":"10.1007/s40273-019-00841-1","title":"Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"TransCanada (Canada)","funders":"Takeda Pharmaceutical Company; Takeda Pharmaceuticals U.S.A.","keywords":"Vedolizumab; Medicine; Health economics; Adalimumab; Ulcerative colitis; Discontinuation; Golimumab; Infliximab; Tofacitinib; Quality-adjusted life year; Cost effectiveness; Internal medicine; Public health; Disease; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004246962,0.000849219,0.003841922,0.001232891,0.0002817409,0.001123457,0.0006944041,0.0008363641,0.001756157],"category_scores_gemma":[0.008647636,0.0005843586,0.009389968,0.001144265,0.0003021582,0.0008147753,0.0006278064,0.0009973324,0.00006067078],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003459765,"about_ca_system_score_gemma":0.002267907,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01169609,"about_ca_topic_score_gemma":0.009957988,"domain_scores_codex":[0.9973475,0.001791317,0.0002666226,0.0002313263,0.0001861372,0.0001770046],"domain_scores_gemma":[0.9971514,0.001695927,0.0006262318,0.00007233089,0.000180015,0.0002742186],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.2256943,0.005188833,0.2115884,0.03239821,0.1404579,0.001419771,0.0004016504,0.2263537,0.002588934,0.002700512,0.003859008,0.1473489],"study_design_scores_gemma":[0.05946447,0.04512048,0.2632023,0.005267225,0.2330763,0.00131614,0.0009355635,0.3795847,0.001471572,0.005423218,0.004800665,0.0003374266],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9200547,0.07226841,0.002435536,0.001348052,0.0001693282,0.0007193059,0.001633407,0.00002959453,0.001341586],"genre_scores_gemma":[0.9927841,0.004804631,0.001065091,0.0002077162,0.00003234148,0.0002813796,0.0006887469,0.000004097197,0.0001319473],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01169609,"threshold_uncertainty_score":0.0251025,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0149218097090462,"score_gpt":0.2817782373427612,"score_spread":0.266856427633715,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}